Hamostaseologie最新文献_第7页

Pathophysiology of Trauma-Induced Coagulopathy. 创伤诱发凝血病的病理生理学。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2215-8936

Herbert Schöchl, Felix C F Schmitt, Marc Maegele

{"title":"Pathophysiology of Trauma-Induced Coagulopathy.","authors":"Herbert Schöchl, Felix C F Schmitt, Marc Maegele","doi":"10.1055/a-2215-8936","DOIUrl":"10.1055/a-2215-8936","url":null,"abstract":"Trauma-induced coagulopathy (TIC) is a complex hemostatic disturbance that can develop early after a major injury. There is no universally accepted definition of TIC. However, TIC primarily refers to the inability to achieve sufficient hemostasis in severely injured trauma patients, resulting in diffuse microvascular and life-threatening bleeding. Endogenous TIC is driven by the combination of hypovolemic shock and substantial tissue injury, resulting in endothelial damage, glycocalyx shedding, upregulated fibrinolysis, fibrinogen depletion, altered thrombin generation, and platelet dysfunction. Exogenous factors such as hypothermia, acidosis, hypokalemia, and dilution due to crystalloid and colloid fluid administration can further exacerbate TIC. Established TIC upon emergency room admission is a prognostic indicator and is strongly associated with poor outcomes. It has been shown that patients with TIC are prone to higher bleeding tendencies, increased requirements for allogeneic blood transfusion, higher complication rates such as multi-organ failure, and an almost fourfold increase in mortality. Thus, early recognition and individualized treatment of TIC is a cornerstone of initial trauma care. However, patients who survive the initial insult switch from hypocoagulability to hypercoagulability, also termed \"late TIC,\" with a high risk of developing thromboembolic complications.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GTH 2024: Building Bridges in Coagulation. GTH 2024：搭建凝血的桥梁

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/s-0044-1779290

Cihan Ay, Christoph Male

引用次数: 0

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies. 癌症患者血栓风险的最新情况：关注新型抗癌免疫疗法。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2215-9909

Florian Moik, Jakob M Riedl, Cornelia Englisch, Cihan Ay

{"title":"Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies.","authors":"Florian Moik, Jakob M Riedl, Cornelia Englisch, Cihan Ay","doi":"10.1055/a-2215-9909","DOIUrl":"10.1055/a-2215-9909","url":null,"abstract":"Thromboembolic complications, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), increase mortality and morbidity, and delay treatment in patients with cancer. Therefore, an increased understanding of underlying risk profiles, the identification of risk factors and predictive biomarkers, and ultimately the development of specific cardiovascular prevention strategies in patients with cancer is needed. Medical anticancer therapies have undergone a remarkable development in recent years with the advent of targeted and immunotherapeutic treatment options, including immune checkpoint inhibitors (ICI), chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engagers (BiTEs). These developments have important implications for the accompanied risk of thromboembolic events in patients with cancer. First, the increased use of these highly effective therapies renders a growing proportion of patients with cancer at risk of thromboembolic events for a prolonged risk period due to an increase in patient survival despite advanced cancer stages. Second, potential direct cardiovascular toxicity and prothrombotic effect of novel anticancer immunotherapies are a matter of ongoing debate, with emerging reports suggesting a relevant risk of VTE and ATE associated with ICI, and relevant dysregulations of hemostasis in the frequently observed cytokine-release syndrome associated with BiTEs and CAR T-cell therapy. The aim of the present narrative review is to summarize the implications of the emerging use of anticancer immunotherapy for thromboembolic events in patients with cancer, and to provide an overview of available data on the rates and risk factors for VTE and ATE associated with ICI, CAR T-cell therapy, and BiTEs.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life. 血栓性血小板减少性紫癜 100 年：死亡与生命的故事》。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2223-9484

Bernhard Lämmle, Karen Vanhoorelbeke, Johanna A Kremer Hovinga, Paul Knöbl

引用次数: 0

Clonal Hematopoiesis and Cardiovascular Risk: Atherosclerosis, Thrombosis, and beyond. 克隆性造血与心血管风险：动脉粥样硬化、血栓形成及其他。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2219-6410

Benedetta Izzi, José J Fuster

引用次数: 0

Vakzin-induzierte Immunthrombozytopenie und Thrombose: Langfristiger Outcome. 疫苗引起的免疫性血小板减少症和血栓形成：长期结果

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/s-0044-1782593

引用次数: 0

PAS: Die Rolle von Natriumcitrat bei längerer Kaltlagerung von Thrombozyten. PAS：柠檬酸钠在血小板长期冷藏中的作用。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/s-0044-1782595

引用次数: 0

The Concept of Thromboinflammation. 血栓性炎症的概念。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-02-01 Epub Date: 2024-02-28 DOI: 10.1055/a-2178-6491

Waltraud C Schrottmaier, Alice Assinger

引用次数: 0

Digenic Inheritance of PROC and SERPINC1 Mutations Contributes to Multiple Sites Venous Thrombosis. PROC 和 SERPINC1 基因突变的双基因遗传导致多部位静脉血栓形成。

IF 3.2 4区医学

Hamostaseologie Pub Date : 2024-01-15 DOI: 10.1055/a-2212-1565

Xiangui Li, Jiabao Zhu, Fanzhen Lv, Wenqi Ma, Weimin Zhou, Wenwen Zhang

{"title":"Digenic Inheritance of PROC and SERPINC1 Mutations Contributes to Multiple Sites Venous Thrombosis.","authors":"Xiangui Li, Jiabao Zhu, Fanzhen Lv, Wenqi Ma, Weimin Zhou, Wenwen Zhang","doi":"10.1055/a-2212-1565","DOIUrl":"https://doi.org/10.1055/a-2212-1565","url":null,"abstract":"Venous thromboembolism (VTE) represents a worldwide health challenge, impacting millions of people each year. The genesis of venous thrombosis is influenced in part by genetic components. Hereditary thrombosis is described as a genetically determined susceptibility to VTE. In the present study, a male patient was referred to our department presenting with multiple venous thrombosis events in different locations. Given a lack of identifiable risk factors, we aimed to investigate the possible genetic factor underlying venous thrombosis. Whole-exome sequencing was employed to examine genes linked to inherited thrombophilia in the proband. Putative variants were subsequently confirmed through Sanger sequencing within the family. The proband was identified as carrying two genetic mutations. One is the novel c.400G > C (p.E134Q) mutation affecting the final nucleotide of exon 5 in the PROC gene, potentially impacting splicing. The other is a previously reported heterozygous nonsense variant c.1016G > A (p.W339X) in the SERPINC1 gene. The proband inherited the former from her mother and the latter from her father. The presence of digenic inheritance in the patient reflects the complex phenotype of venous thrombosis and demonstrates the significance of an unbiased approach to detect pathogenic variants, especially in patients with a high risk of hereditary thrombosis.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. Emicizumab治疗获得性血友病A: GTH-AHA工作组的共识建议

IF 3.2 4区医学

Hamostaseologie Pub Date : 2023-12-04 DOI: 10.1055/a-2197-9738

Christian Pfrepper, Robert Klamroth, Johannes Oldenburg, Katharina Holstein, Hermann Eichler, Christina Hart, Patrick Moehnle, Kristina Schilling, Karolin Trautmann-Grill, Mohammed Alrifai, Cihan Ay, Wolfgang Miesbach, Paul Knoebl, Andreas Tiede

{"title":"Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.","authors":"Christian Pfrepper, Robert Klamroth, Johannes Oldenburg, Katharina Holstein, Hermann Eichler, Christina Hart, Patrick Moehnle, Kristina Schilling, Karolin Trautmann-Grill, Mohammed Alrifai, Cihan Ay, Wolfgang Miesbach, Paul Knoebl, Andreas Tiede","doi":"10.1055/a-2197-9738","DOIUrl":"https://doi.org/10.1055/a-2197-9738","url":null,"abstract":"Background: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). Standard treatment consists of bleeding control with bypassing agents and immunosuppressive therapy. Emicizumab is a bispecific antibody that mimics the function of activated FVIII irrespective of the presence of neutralizing antibodies. Recently, the GTH-AHA-EMI study demonstrated that emicizumab prevents bleeds and allows to postpone immunosuppression, which may influence future treatment strategies.Aim: To provide clinical practice recommendations on the use of emicizumab in AHA.Methods: A Delphi procedure was conducted among 33 experts from 16 German and Austrian hemophilia care centers. Statements were scored on a scale of 1 to 9, and agreement was defined as a score of ≥7. Consensus was defined as ≥75% agreement among participants, and strong consensus as ≥95% agreement.Results: Strong consensus was reached that emicizumab is effective for bleed prophylaxis and should be considered from the time of diagnosis (100% consensus). A fast-loading regimen of 6 mg/kg on day 1 and 3 mg/kg on day 2 should be used if rapid bleeding prophylaxis is required (94%). Maintenance doses of 1.5 mg/kg once weekly should be given (91%). Immunosuppression should be offered to patients on emicizumab if they are eligible based on physical status (97%). Emicizumab should be discontinued when remission of AHA is achieved (97%).Conclusion: These GTH consensus recommendations provide guidance to physicians on the use of emicizumab in AHA and follow the results of clinical trials that have shown emicizumab is effective in preventing bleeding in AHA.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138483537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0